Feed / QURE

uniQure N.V.

QURE

Healthcare · 44.51 +0.1% today

Isolated · not yet confirmedMarket checked 11 Sept, 15:55 GMT-4

Market read

uniQure N.V.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 10 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.

Company+0.1% todayVolume comparison unavailable
Market group0 of 10 activeMixed Sector Themes · unavailable
Disclosed network0 of 2 confirmingNo filing-linked name is confirming now
What would change this read
  • QURE's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if QURE's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Biotechnology

No new filing conclusion is available. 0 of 10 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • QURE's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 12, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations320
Usable filing statements41
Verified relationships13
Evidence supporting the case

No qualifying supportive evidence was identified.

Evidence challenging the case
  • Latest annual revenue changed -40.6% year over year.
  • Operating margin changed -471.8 percentage points in the latest annual period.
  • Net margin changed -352.6 percentage points in the latest annual period.
  • Diluted shares increased 18.2% in the latest annual period.
  • Credit and interest rates has repeated adverse evidence across 4 filings.
Questions before a position
  • EV/sales is 3802% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 11, 2026

44.51
6m+323.9%12m+173.7%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$524.0M+1296.8%$7.04+5.3%
2022-12-31$106.5M-79.7%$-2.71-0.2%
2023-12-31$15.8M-85.1%$-6.47+2.0%
2024-12-31$27.1M+71.2%$-4.92+2.1%
2025-12-31$16.1M-40.6%$-3.46+18.2%

What management says matters

Persistent and emerging business drivers

Credit and interest ratesnegative · 4 filings
Our interest expense decreased by $0.4 million, primarily due to improved terms following the September 2025 amendment as well as a decrease in market interest rates.
10-Q · May 5, 2026
Supply chain and availabilitymixed · 2 filings
As a component of our broader efforts to focus our business and reduce operating expenses, the Lexington Transaction is expected to reduce our cash burn as a result of a reduction in facility and personnel-related costs, among others.
10-Q · Nov 10, 2025
Product pipeline and R&Dmixed · 1 filings
The carrying amount of cash and cash equivalents, accounts receivable from our licensing and collaboration partner, other assets, accounts payable, accrued expenses and other current liabilities reflected in the Consolidated Balance Sheets approximate their f…
10-K · Mar 2, 2026
Restructuring and cost reductionsnegative · 1 filings
The decrease was primarily related to the reduction in personnel and contractors as a result of the divestment of our commercial manufacturing activities and a reduction in expense from the restructuring that occurred in August 2024; ● We incurred $5.3 millio…
10-Q · Jul 29, 2025

Valuation discipline

Descriptive valuation snapshot

Price/sales 159.0× · EV/sales 157.1×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

44.51+0.1% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for QURE. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for QURE. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind QURE

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

HTGCHercules Capital, Inc.lenderMar 2, 2026

Hercules Loan Amendment In September 2025, we entered into a $175.0 million senior secured term loan facility (the “2025 Amended Facility”) with Hercules Capital, Inc.

Depended on by

CRSPCRISPR Therapeutics AGcompetitorFeb 12, 2026

These companies may also serve as competitive threats and include 4D Molecular Therapeutics, AskBio, Passage Bio, Sarepta Therapeutics, UniQure, and Voyager Therapeutics.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

QURE is currently a Early Follower in the organic co-movement group Mixed Sector Themes. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for QURE; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.